We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850).
- Authors
Eron, J J, Jr; Smeaton, L M; Fiscus, S A; Gulick, R M; Currier, J S; Lennox, J L; D'Aquila, R T; Rogers, M D; Tung, R; Murphy, R L
- Abstract
Antiretroviral therapy may lead to decreased shedding of human immunodeficiency virus type 1 (HIV-1) in genital secretions. Thirty men, 19 receiving amprenavir and 11 receiving amprenavir, zidovudine, and lamivudine, donated blood and semen while undergoing treatment, to evaluate the effects of these medications on HIV-1 shedding in semen. Before therapy, 4 men had HIV-1 RNA levels in seminal plasma >6.0 log10 (1 million) copies/mL, markedly higher than levels in blood plasma. Most men (77%) had HIV-1 RNA levels in seminal plasma below the limit of quantification during therapy. Amprenavir alone suppressed HIV-1 RNA levels to <400 copies/mL in seminal plasma in the majority of patients, the first direct demonstration of the antiretroviral effects of a protease inhibitor in the male genital tract. However, 8 men (27%) had measurable HIV-1 in seminal plasma at their last study visit, 4 with increasing levels. Persistent replication of HIV in the genital tract may have implications for the selection of resistant virus and sexual transmission of HIV-1.
- Publication
The Journal of infectious diseases, 2000, Vol 181, Issue 5, p1622
- ISSN
0022-1899
- Publication type
Journal Article
- DOI
10.1086/315447